SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Enzymotec Ltd. ...
2014年9月23日 - 2:04AM
ビジネスワイヤ(英語)
The securities litigation law firm of Brower Piven, A
Professional Corporation, announces that a class action lawsuit has
been commenced in the United States District Court for the District
of New Jersey on behalf of purchasers of Enzymotec Ltd.
(“Enzymotec” or the “Company”) (Nasdaq: ENZY) securities pursuant
and/or traceable to the Company’s Registration Statement and
Prospectus (“Offering Documents”) issued in connection with the
Company’s initial public offering on or about September 27, 2013,
and/or on the open market between September 27, 2013 and August 4,
2014, inclusive (the “Class Period”).
If you have suffered a loss from investment in Enzymotec
securities purchased on or after September 27, 2013 and held
through the revelation of negative information during and/or at the
end of the Class Period, as described below, and would like to
learn more about this lawsuit and your ability to participate as a
lead plaintiff, without cost or obligation to you, please visit our
website at http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven
either by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. No class has yet been certified in the above action.
Members of the Class will be represented by the lead plaintiff and
counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class,
you must apply to be appointed lead plaintiff no later than
November 4, 2014 and be selected by the Court. The lead plaintiff
will direct the litigation and participate in important decisions
including whether to accept a settlement and how much of a
settlement to accept for the Class in the action. The lead
plaintiff will be selected from among applicants claiming the
largest loss from investment in Company units during the Class
Period. Brower Piven also encourages anyone with information
regarding the Company’s conduct during the period in question to
contact the firm, including whistleblowers, former employees,
shareholders and others.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 and the Securities Act of 1933 by
virtue of the defendants’ failure to disclose in the Offering
Documents and during the Class Period that Enzymotec’s Chinese
business was subject to material and readily identifiable
compliance regulations from the Chinese government, that the
Company’s baby formula business in China was jeopardized and
subject to increased volatility and decreased revenues and that the
Company’s joint venture with AarhusKarlshamn AB, which marketed the
popular InFat product, was crumbling and subjected the Company to
liability and decreased revenues. According to the complaint,
following the Company’s May 14, 2014 announcement that “Chinese
regulations require infant formula manufacturers to make certain
changes to their production chain,” and as a result the Company’s
revenues were lower, and its August 5, 2014 disclosure of the
increased impact of the Chinese regulations on its sales of infant
formula and of its financial results that were significantly lower
than the prior year in almost all respects, the value of
Enzymotec’s shares declined significantly.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you
choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other
counsel of your choice. You need take no action at this time to be
a member of the class.
Brower Piven, A Professional CorporationCharles J. Piven,
410-415-66161925 Old Valley RoadStevenson, Maryland
21153hoffman@browerpiven.com
ENZYMOTEC LTD. (NASDAQ:ENZY)
過去 株価チャート
から 6 2024 まで 7 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
過去 株価チャート
から 7 2023 まで 7 2024